Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
about
Prospects for vaccine prevention of meningococcal infectionPotential Roles of Fungal Extracellular Vesicles during InfectionStandardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assayEscherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies.Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugatesThe meningococcus and mechanisms of pathogenicityHumoral immune responses to Neisseria meningitidis in children.Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.Studies on gonococcus infection. XVIII. 125I-labeled peptide mapping of the major protein of the gonococcal cell wall outer membraneProtection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.Bexsero® chronicle.Meningococcal disease in ScandinaviaExpression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines.Sequence of the structural gene (rmpM) for the class 4 outer membrane protein of Neisseria meningitidis, homology of the protein to gonococcal protein III and Escherichia coli OmpA, and construction of meningococcal strains that lack class 4 proteinAssignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccineAntibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease.Natural bactericidal activity of human serum against Neisseria meningitidis isolates of different serogroups and serotypesProtection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparationsProtection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogensProtection against group B meningococcal disease. II. Infection and resulting immunity in a guinea pig model.Monoclonal antibodies directed against a cell surface-exposed outer membrane protein of Haemophilus influenzae type b.Identification of immunogenic outer membrane proteins of Haemophilus influenzae type b in the infant rat model system.Identification of immunogenic outer membrane proteins of Pasteurella multocida 3:A in rabbits.Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in manDevelopment of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse modelHuman opsonins to meningococci after vaccination.Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidisAntibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigenSpin membrane immunoassay for use in meningococcal serologyEnzyme-linked immunosorbent assay compared with immunoprecipitation for serotyping Neisseria meningitidis and its use in demonstrating serotype polymorphism.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Could autoimmunity be induced by vaccination?Heat-modifiable outer membrane proteins of Neisseria meningitidis and their organization within the membrane.Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978.A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge modelOuter membrane antigens of Neisseria meningitidis group B serotype 2 studied by crossed immunoelectrophoresis.
P2860
Q24537338-99748B45-5BB8-456F-91D5-234076EB1187Q26743448-69DA5CB4-F3F3-4C49-8F2D-5C32075EA5F2Q28344521-72000089-B65D-489F-AC06-578970D16039Q30442755-F50A7CC1-6D98-4EE4-B3C1-C7BC854175E1Q33595722-95978F06-B9FF-4EFE-A56F-5BB082C7825DQ33626434-6DD1741D-EC4D-4A7F-91A4-0257C7B3D7ADQ33867340-98A118DE-3A97-41E1-BA77-E96C20EA3C51Q33968762-CB5094E3-D2CB-4848-A016-6D35C8FBF578Q34080424-BC5AAC5D-5F19-4236-BF55-4B0409332E1DQ34094054-15D9822B-C5C5-44EC-8CC5-BDAC7E3315E7Q34541047-E93CD180-1783-4EE6-BEC2-BACDDB74495EQ34562726-CAA73737-2E37-42B0-BDE8-2300EA7E0D20Q34760360-3F1109EA-EAA1-4ECE-BD7F-B5A3C83BC730Q35103809-BAA86045-778A-40FE-A1A2-883944601377Q35111410-5AE58B2B-F9D5-4865-939B-7A416D305D6AQ35224131-AEEF70B2-661A-425C-994D-BB1D979E55ECQ35229074-A1C94B9B-0D77-44B9-B90D-B942075DAA25Q35437531-4E01B7DD-2C58-4EC8-ACB0-097AF4206CB6Q36328732-5D77990A-1AC5-42D0-9F93-09AD6C2669C3Q36328942-7628D462-8E99-4731-B2C2-8B584C33C12CQ36329652-5E96E844-4B84-459B-930F-DCAAAE02C151Q36329679-DF5FED90-9C7B-4D65-84A5-9AFD192A199EQ36339989-3D4DE7D2-4241-4E83-9D3A-C10E05961F41Q36439022-1B7FF390-E490-442C-98F3-26EC66625EF4Q36448711-E25EDE16-74F0-4BBB-AFC5-C2BBBBCDD2F8Q36996779-A1ABB687-7143-4D58-88D3-5F4FDE28CBB8Q37038027-6A22130E-0E34-4762-B4AF-B5BAE481D332Q37041494-0FF78A2E-CD23-443D-8880-F98997EE203FQ37042683-4175D79E-7582-46A8-B4E3-C3ADBBA467FAQ37111150-FC359BEB-AC5C-4819-B790-69BBF97B69F1Q37152841-89512318-A16A-491F-83E1-F005B61211C9Q37213235-4DD2AA0F-96E3-4A38-A34A-964CDE21FE21Q37258317-5D996AEC-560A-4478-A3C4-AEF0DF755A0DQ37333667-891A2788-AB02-4714-B9D4-1AFBD7568A00Q37514748-92EB2EE2-8174-4FD8-8A67-9C194A704638Q37762550-581ADCB5-2202-4482-A7D2-A5E5DA9BA2F7Q39634202-34E117CE-5170-436C-A52C-4E8FC724F1BDQ39655576-46E4D2A7-FDAF-4C49-985F-980B4B3426B5Q39671989-1504DF2C-414C-488C-B5C0-3E4EC748B4C0Q39694152-CFDE51D7-F4FD-4065-8068-280CE6689053
P2860
Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
Protection against group B men ...... tection in a guinea pig model.
@ast
Protection against group B men ...... tection in a guinea pig model.
@en
type
label
Protection against group B men ...... tection in a guinea pig model.
@ast
Protection against group B men ...... tection in a guinea pig model.
@en
prefLabel
Protection against group B men ...... tection in a guinea pig model.
@ast
Protection against group B men ...... tection in a guinea pig model.
@en
P2860
P356
P1476
Protection against group B men ...... tection in a guinea pig model.
@en
P2093
P2860
P304
P356
10.1084/JEM.147.3.629
P407
P577
1978-03-01T00:00:00Z